Compare JMSB & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JMSB | PROF |
|---|---|---|
| Founded | 2005 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 270.0M | 230.4M |
| IPO Year | N/A | N/A |
| Metric | JMSB | PROF |
|---|---|---|
| Price | $19.85 | $8.21 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $22.50 | $12.00 |
| AVG Volume (30 Days) | 17.8K | ★ 288.0K |
| Earning Date | 01-30-2026 | 03-05-2026 |
| Dividend Yield | ★ 1.51% | N/A |
| EPS Growth | ★ 18.50 | N/A |
| EPS | ★ 1.40 | N/A |
| Revenue | ★ $59,274,000.00 | $14,297,000.00 |
| Revenue This Year | $19.50 | $64.23 |
| Revenue Next Year | $12.72 | $113.06 |
| P/E Ratio | $14.17 | ★ N/A |
| Revenue Growth | 11.69 | ★ 67.94 |
| 52 Week Low | $13.81 | $3.76 |
| 52 Week High | $21.58 | $8.95 |
| Indicator | JMSB | PROF |
|---|---|---|
| Relative Strength Index (RSI) | 48.17 | 57.22 |
| Support Level | $19.35 | $7.45 |
| Resistance Level | $20.35 | $8.95 |
| Average True Range (ATR) | 0.41 | 0.58 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 41.67 | 61.13 |
John Marshall Bancorp Inc is a bank holding company. Through its banking subsidiary, it offers banking products and financial services to small to medium-sized businesses, professional corporations, non-profits, and individuals. The products and services offered by the company include commercial checking, savings, and money market accounts, certificates of deposit, treasury and cash management services, commercial and industrial loans, commercial real estate loans, residential and commercial construction and development loans, online banking, and mobile banking. The firm serves local businesses, professionals, individuals, and families throughout the Washington, D.C. metropolitan area.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the image-guided ablation of diseased tissue utilizing its platform technologies and leveraging the healthcare system's existing imaging infrastructure. The company's product TULSA-PRO system combines real-time MRI, robotically driven transurethral sweeping-action thermal ultrasound with closed-loop temperature feedback control for the ablation of prostate tissue. The product is comprised of one-time-use devices and durable equipment that are used in conjunction with a customer's existing MRI scanner.